Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by Redbaron2211on Apr 09, 2021 12:32pm
104 Views
Post# 32967125

RE:RE:RE:RE:RE:RE:RE:RE:RE:Presentation

RE:RE:RE:RE:RE:RE:RE:RE:RE:PresentationBio you can check the value of peers all you want Semma was bought out for 950mil US preclinical around 1.3mil Can it will not change.   SGTX has had valuations up to almost 2b but they are also preclinical and simply do not have the science to back it up, some stagnation and retracement is only natural.  In the meantime Sernova is well into clinical trials w/ very positive results and likely to see multiple indications in the clinic soon.  Grasping at straws trying to understand what's going on behind the NDAs does no one any service.  Fact is you are making assumptions.  None of us know where big pharma stands in current negotiations and that wild card remains a real possibility.    
 
Re: changing the board.  Who do those that are so quick to act have in mind as a replacement?
<< Previous
Bullboard Posts
Next >>